This meeting will address recent advances in the area of protein-protein interactions. Topics will include: inducing protein degradation using small molecules, protein engineering and synthetic biology, integration of computational and experimental methods to study PPIs, characterisation and identification of new PPI inhibitors and lead optimization challenges for molecules targeting PPIs from case studies in drug discovery. Speakers from both industry and academia will describe strategies for addressing these challenges whilst showcasing the opportunity for creativity and innovation.

Dr Philip Fallon (Group Leader, Medicinal Chemistry), will be at the event and presenting a talk entitled “A new class of RAS-effector protein-protein interaction inhibitors derived using an intracellular antibody fragment”.